Inmune Bio, Inc. cotiza a 1.78 USD y tiene una capitalización bursátil de $49M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's deve…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.05 | $-0.20 | $-0.18 |
| Estimado | $-0.18 | $-0.20 | $-0.18 | $-0.27 |
| Sorpresa | — | +75.0% | -11.1% | +33.3% |
| Métrica | INMB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -94766.0% | -38.6% | -94727.4% |
| Net Margin | -91866.0% | -33.6% | -91832.4% |
| FCF Margin | -47248.0% | -13.9% | -47234.1% |
| ROE | -195.3% | -40.4% | -154.9% |
| ROA | -142.0% | -32.0% | -110.0% |
| Current Ratio | 3.55 | 2.84 | +0.71 |
| Debt / Equity | — | 0.28 | — |